Last reviewed · How we verify
Dihydroartemisinin
Dihydroartemisinin is a Small molecule drug developed by Shanghai Zhongshan Hospital. It is currently FDA-approved for Malaria. Also known as: No other names, 1st group.
Dihydroartemisinin is a semi-synthetic derivative of artemisinin and a small molecule that acts as a binding agent for Ferriprotoporphyrin IX. It is used to treat malaria, including uncomplicated malaria and vivax malaria, and is available as a standalone drug or in combination with piperaquine.
At a glance
| Generic name | Dihydroartemisinin |
|---|---|
| Also known as | No other names, 1st group |
| Sponsor | Shanghai Zhongshan Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Malaria
Common side effects
Key clinical trials
- A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults (PHASE1)
- Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy (EARLY_PHASE1)
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana (NA)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission (PHASE4)
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Mass Vaccine and Drug Administration, Bangladesh (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dihydroartemisinin CI brief — competitive landscape report
- Dihydroartemisinin updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI
Frequently asked questions about Dihydroartemisinin
What is Dihydroartemisinin?
What is Dihydroartemisinin used for?
Who makes Dihydroartemisinin?
Is Dihydroartemisinin also known as anything else?
What development phase is Dihydroartemisinin in?
Related
- Manufacturer: Shanghai Zhongshan Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Malaria
- Also known as: No other names, 1st group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing